{{Drugbox
| IUPAC_name = 2-<nowiki/>{4-[4-(4-chloro-1''H''-pyrazol-1-yl)butyl]piperazin-1-yl}pyrimidine
| image = Lesopitron.png

<!--Clinical data-->
| tradename =  
| pregnancy_category =  
| legal_status = Uncontrolled
| routes_of_administration = Oral

<!--Pharmacokinetic data-->
| bioavailability =  
| metabolism =  
| elimination_half-life =  
| excretion =  

<!--Identifiers-->
| CAS_number = 132449-46-8
| ATC_prefix = none
| ATC_suffix =  
| PubChem = 60813
| ChemSpiderID = 54801
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = H1CGM4755H

<!--Chemical data-->
| C=15 | H=21 | Cl=1 | N=6 
| molecular_weight = 320.82 g/mol
| smiles = Clc1cn(nc1)CCCCN3CCN(c2ncccn2)CC3
}}

'''Lesopitron''' ('''E-4424''') is a [[binding selectivity|selective]] [[full agonist]] of the [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] which is [[chemical structure|structurally]] related to the [[azapirone]]s.<ref name="pmid8026543">{{cite journal  |vauthors=Haj-Dahmane S, Jolas T, Laporte AM, etal | title = Interactions of lesopitron (E-4424) with central 5-HT1A receptors: in vitro and in vivo studies in the rat | journal = European Journal of Pharmacology | volume = 255 | issue = 1-3 | pages = 185–96 |date=April 1994 | pmid = 8026543 | doi = 10.1016/0014-2999(94)90097-3| url = }}</ref> In 2001 it was under development by [[Esteve]] as an [[anxiolytic]] for the treatment of [[generalized anxiety disorder]] (GAD).<ref name="pmid16032484">{{cite journal | author = Micheli F | title = Lesopitron (Esteve) | journal = IDrugs : the Investigational Drugs Journal | volume = 4 | issue = 2 | pages = 218–24 |date=February 2001 | pmid = 16032484 | doi = | url = }}</ref><ref name="pmid10676820">{{cite journal  |vauthors=Fresquet A, Sust M, Lloret A, etal | title = Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder | journal = The Annals of Pharmacotherapy | volume = 34 | issue = 2 | pages = 147–53 |date=February 2000 | pmid = 10676820 | doi = 10.1345/aph.19041| url = http://www.theannals.com/cgi/pmidlookup?view=long&pmid=10676820}}</ref> It made it to [[Clinical_trial#Phase_II|phase II]] [[clinical trial]]s but was apparently discontinued as no new information on lesopitron has surfaced since.<ref name="pmid16032484">{{cite journal | author = Micheli F | title = Lesopitron (Esteve) | journal = IDrugs : the Investigational Drugs Journal | volume = 4 | issue = 2 | pages = 218–24 |date=February 2001 | pmid = 16032484 | doi = | url = }}</ref><ref name="pmid10676820">{{cite journal  |vauthors=Fresquet A, Sust M, Lloret A, etal | title = Efficacy and safety of lesopitron in outpatients with generalized anxiety disorder | journal = The Annals of Pharmacotherapy | volume = 34 | issue = 2 | pages = 147–53 |date=February 2000 | pmid = 10676820 | doi = 10.1345/aph.19041| url = http://www.theannals.com/cgi/pmidlookup?view=long&pmid=10676820}}</ref>

== See also ==
* [[Sunepitron]]

== References ==
{{Reflist}}


{{Anxiolytics}}
{{Antidepressants}}
{{Serotonergics}}

[[Category:Piperazines]]
[[Category:Pyrazoles]]
[[Category:Pyrimidines]]
[[Category:Chloroarenes]]